Raymond James Financial Services Advisors, Inc. Avidity Biosciences, Inc. Transaction History
Raymond James Financial Services Advisors, Inc.
- $73.5 Billion
- Q3 2024
A detailed history of Raymond James Financial Services Advisors, Inc. transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Raymond James Financial Services Advisors, Inc. holds 115,403 shares of RNA stock, worth $5.1 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
115,403
Previous 112,033
3.01%
Holding current value
$5.1 Million
Previous $4.58 Million
15.82%
% of portfolio
0.01%
Previous 0.01%
Shares
8 transactions
Others Institutions Holding RNA
# of Institutions
232Shares Held
119MCall Options Held
340KPut Options Held
145K-
Price T Rowe Associates Inc Baltimore, MD10.8MShares$478 Million0.03% of portfolio
-
Janus Henderson Group PLC London, X010.8MShares$476 Million0.16% of portfolio
-
Rtw Investments, LP New York, NY9.62MShares$425 Million4.2% of portfolio
-
Wellington Management Group LLP Boston, MA9.25MShares$409 Million0.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.25MShares$409 Million0.0% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $2.3B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...